Multiplex Assay Kit for Follistatin Like Protein 1 (FSTL1) ,etc. by FLIA (Flow Luminescence Immunoassay) 
FRP; FSL1; Follistatin-related protein 1
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 449.00 US$ 467.00 US$ 492.00 US$ 527.00 US$ 562.00 US$ 613.00 US$ 691.00 US$ 864.00
- Quantity
Overview
Properties
- Product No.LMJ085Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryReproductive science
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Follistatin Like Protein 1 (FSTL1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Follistatin Like Protein 1 (FSTL1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 83-103 | 93 |
| EDTA plasma(n=5) | 89-98 | 95 |
| heparin plasma(n=5) | 88-102 | 97 |
| sodium citrate plasma(n=5) | 92-104 | 96 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Follistatin Like Protein 1 (FSTL1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Follistatin Like Protein 1 (FSTL1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Follistatin Like Protein 1 (FSTL1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 89-96% | 96-105% | 93-105% | 85-104% |
| EDTA plasma(n=5) | 78-104% | 81-93% | 80-89% | 91-99% |
| heparin plasma(n=5) | 94-104% | 92-103% | 88-101% | 96-103% |
| sodium citrate plasma(n=5) | 79-97% | 80-101% | 80-93% | 90-104% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:FSTL1) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease.PubMed: 22660800
- Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cellsPubmed: 23419164
- Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferationPubmed:25118038
- Growth Differentiation Factor-15 (GDF-15) Levels Are Associated with Cardiac and Renal Injury in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary BypassPubmed:25171167
- Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistancePubMed: 26199111
- Association of Circulating Follistatin-Like 1 Levels with Inflammatory and Oxidative Stress Markers in Healthy Menpmc:PMC4856269
- Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction.pubmed:27430031
- Follistatin like-1 aggravates silica-induced mouse lung injuryPMC5428474
- Plasma follistatin-like protein 1 is correlated with disease severity in patients with acute pulmonary embolism and predicts short-term mortalityISSN:1936-2625
- High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy statePubmed: 30745500
- Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous …Pubmed: 31034503
- Improved early detection of ovarian cancer using longitudinal multimarker modelsPubmed: 31937926
- Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in micePubmed: 32933544
- Effects of acute endurance exercise on follistatin-like 1 and apelin in the circulation and metabolic organs in ratsPubmed: 32412800
- Prognostic impact of transcardiac gradient of follistatin-like 1 reflecting hemodynamics in patients with dilated cardiomyopathy34334268
- Association between Plasma Follistatin-like Protein 1 Levels and the Presence and Severity of Coronary Artery Disease34853217